• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of procbhomepageaboutsubmitalertseditorial board
Proc Biol Sci. Jul 7, 2000; 267(1450): 1347–1354.
PMCID: PMC1690670

HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?

Abstract

The biphasic decay of blood viraemia in patients being treated for human immunodeficiency virus type 1 (HIV-1) infection has been explained as the decay of two distinct populations of cells: the rapid death of productively infected cells followed by the much slower elimination of a second population the identity of which remains unknown. Here we advance an alternative explanation based on the immune response against a single population of infected cells. We show that the biphasic decay can be explained simply, without invoking multiple compartments: viral load falls quickly while cytotoxic T lymphocytes (CTL) are still abundant, and more slowly as CTL disappear. We propose a method to test this idea, and develop a framework that is readily applicable to treatment of other infections.

Full Text

The Full Text of this article is available as a PDF (304K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aillet F, Masutani H, Elbim C, Raoul H, Chêne L, Nugeyre MT, Paya C, Barré-Sinoussi F, Gougerot-Pocidalo MA, Israël N. Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines. J Virol. 1998 Dec;72(12):9698–9705. [PMC free article] [PubMed]
  • Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996 Oct 4;274(5284):94–96. [PubMed]
  • Barker E, Bossart KN, Levy JA. Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of beta-chemokines. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1725–1729. [PMC free article] [PubMed]
  • Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6971–6976. [PMC free article] [PubMed]
  • Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997 Feb;3(2):205–211. [PubMed]
  • Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999 Mar 12;283(5408):1748–1752. [PubMed]
  • Conti L, Rainaldi G, Matarrese P, Varano B, Rivabene R, Columba S, Sato A, Belardelli F, Malorni W, Gessani S. The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS. J Exp Med. 1998 Feb 2;187(3):403–413. [PMC free article] [PubMed]
  • De Boer RJ, Perelson AS. Target cell limited and immune control models of HIV infection: a comparison. J Theor Biol. 1998 Feb 7;190(3):201–214. [PubMed]
  • Ding AA, Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Math Biosci. 1999 Aug;160(1):63–82. [PubMed]
  • Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell. 1998 May 29;93(5):665–671. [PubMed]
  • Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK, Davis MM, Merigan TC. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999 Feb 1;162(3):1780–1788. [PubMed]
  • Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999 Mar 15;189(6):991–998. [PMC free article] [PubMed]
  • Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med. 1999 May;5(5):535–541. [PubMed]
  • Klenerman P, Zinkernagel RM. What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev. 1997 Oct;159:5–16. [PubMed]
  • Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, Forman MA, Letvin NL. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol. 1999 May 1;162(9):5127–5133. [PubMed]
  • Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature. 1994 Jun 23;369(6482):648–652. [PubMed]
  • Meinl E, Fickenscher H, Thome M, Tschopp J, Fleckenstein B. Anti-apoptotic strategies of lymphotropic viruses. Immunol Today. 1998 Oct;19(10):474–479. [PubMed]
  • Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998 Oct 2;282(5386):103–107. [PubMed]
  • Nixon DF, Douek D, Kuebler PJ, Jin X, Vesanen M, Bonhoeffer S, Cao Y, Koup RA, Ho DD, Markowitz M. Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunol Lett. 1999 Mar;66(1-3):219–228. [PubMed]
  • Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998 Aug 20;12(12):1483–1490. [PubMed]
  • Nowak MA, Bangham CR. Population dynamics of immune responses to persistent viruses. Science. 1996 Apr 5;272(5258):74–79. [PubMed]
  • Nowak MA, Bonhoeffer S, Shaw GM, May RM. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol. 1997 Jan 21;184(2):203–217. [PubMed]
  • Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998 Mar 27;279(5359):2103–2106. [PubMed]
  • Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999 Jan;73(1):797–800. [PMC free article] [PubMed]
  • Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. [PubMed]
  • Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997 May 8;387(6629):188–191. [PubMed]
  • Sandstrom PA, Pardi D, Goldsmith CS, Chengying D, Diamond AM, Folks TM. bc1-2 expression facilitates human immunodeficiency virus type-1 mediated cytopathic effects during acute spreading infections. J Virol. 1996 Jul;70(7):4617–4622. [PMC free article] [PubMed]
  • Scheuring UJ, Sabzevari H, Corbeil J, Theofilopoulos AN. Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells. AIDS. 1999 Feb 4;13(2):167–175. [PubMed]
  • Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA. 1998 Jul 1;280(1):67–71. [PubMed]
  • Wang L, Klimpel GR, Planas JM, Li H, Cloyd MW. Apoptotic killing of CD4+ T lymphocytes in HIV-1-infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells. Virology. 1998 Feb 15;241(2):169–180. [PubMed]
  • Wang Z, Morris GF, Reed JC, Kelly GD, Morris CB. Activation of Bcl-2 promoter-directed gene expression by the human immunodeficiency virus type-1 Tat protein. Virology. 1999 May 10;257(2):502–510. [PubMed]
  • Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. [PubMed]
  • Wodarz D, Nowak MA. The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Proc Biol Sci. 1998 Nov 22;265(1411):2149–2158. [PMC free article] [PubMed]
  • Zinkernagel RM, Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today. 1994 Jun;15(6):262–268. [PubMed]

Articles from Proceedings of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...